MK-677 (Ibutamoren) Biohacker and Longevity Stack Protocol: Doses, Cycles, Labs, and Evidence

What Is MK-677 and Why Do Longevity Researchers Use It?

MK-677 is an orally bioavailable, non-peptide agonist of the ghrelin receptor that stimulates pituitary release of growth hormone (GH) and subsequently raises insulin-like growth factor 1 (IGF-1). Unlike injectable GH, it preserves the natural pulsatile pattern of GH secretion, which many clinicians consider safer for long-term use.

Mechanism of Action

MK-677 binds the GH secretagogue receptor 1a (GHSR-1a), the same receptor activated by the hunger hormone ghrelin. This binding triggers a GH pulse from the pituitary without suppressing the body's own hypothalamic-pituitary axis feedback. A 2-year randomized controlled trial in elderly adults (N=65) showed that 25 mg/day of MK-677 increased mean IGF-1 by roughly 40% compared with placebo, and that GH pulse amplitude rose significantly without altering GH pulse frequency (Nass et al., 2008, J Clin Endocrinol Metab).

Why the Longevity Community Is Interested

Age-related decline in GH and IGF-1 (somatopause) tracks closely with losses of lean mass, bone density, and sleep quality. Raising IGF-1 back toward younger reference ranges is the stated rationale in longevity circles. A 12-month RCT (N=187) of MK-677 in healthy older adults demonstrated a statistically significant increase in fat-free mass (approximately 1.4 kg over placebo, P<0.05) and improvements in functional measures (Murphy et al., 1998, Am J Clin Nutr). The tradeoff, discussed in detail below, is a measurable deterioration in insulin sensitivity.

Regulatory Status

MK-677 is not approved by the FDA for any indication. It has been studied under IND applications and remains a research compound. Prescribing or dispensing it outside a clinical trial is off-label, and the FDA has issued warnings about research chemicals sold as dietary supplements (FDA, 2017). Patients and clinicians operate in a legal gray zone that requires written informed consent and rigorous monitoring.

Biohacker Protocol: Dosing, Timing, and Cycling

The goal of a longevity-oriented MK-677 protocol is to raise IGF-1 into a target range without generating sustained hyperinsulinemia or fluid-driven blood pressure changes. The protocol below reflects the evidence base and is appropriate only under physician supervision.

Starting Dose and Titration

Most practitioners start at 10 mg nightly and hold for 4 weeks before considering an increase. This low-start strategy was validated in a dose-escalation study showing that 10 mg produced 52% of the IGF-1 response of 25 mg, with meaningfully fewer side effects at the lower dose (Chapman et al., 1996, J Clin Endocrinol Metab).

• Week 1 to 4: 10 mg orally at bedtime
• Week 5 to 12: increase to 15 to 20 mg if IGF-1 target not reached and fasting glucose remains <100 mg/dL
• Week 13 to 24: maintain at 20 to 25 mg only if labs remain within acceptable range

Taking MK-677 at bedtime aligns the drug-induced GH pulse with the natural nocturnal GH peak, which may reduce daytime hunger (a common complaint at higher doses) and may improve slow-wave sleep architecture (Copinschi et al., 1997, Sleep).

Cycle Length and Off-Periods

A 12 to 24 week active cycle followed by a 4 to 8 week washout is the structure used in most published trials. The Nass 2-year trial ran continuously, but continuous use produced progressive fluid retention and worsening of fasting glucose in a subset of participants (Nass et al., 2008). Off periods allow insulin sensitivity to recover and give clinicians a baseline IGF-1 reading unaffected by exogenous stimulation. Retesting IGF-1 and fasting glucose 4 weeks into the washout provides the clearest picture of where a patient's axis truly sits.

Oral Administration Details

MK-677 is taken by mouth, typically as a liquid solution or capsule. No injection is required. Bioavailability is approximately 60 to 70% regardless of fed or fasted state, though some users report blunted hunger side effects when taking it with a small protein-containing meal (Pong et al., 1996, Mol Endocrinol).

IGF-1 Targeting: What Numbers to Aim For

Longevity-protocol IGF-1 targets are not standardized by any guideline body. The Endocrine Society's clinical practice guideline on GH deficiency in adults recommends an IGF-1 target of 0 to +2 standard deviations for age and sex (Molitch et al., 2011, J Clin Endocrinol Metab). Practically, this means:

• Ages 30 to 40: target IGF-1 of 175 to 280 ng/mL
• Ages 40 to 50: target IGF-1 of 155 to 250 ng/mL
• Ages 50 to 65: target IGF-1 of 135 to 220 ng/mL

Exceeding 300 ng/mL in middle-aged adults is associated with increased cancer risk signals in epidemiological data. A large prospective cohort (N=21,457) showed that IGF-1 in the highest quartile correlated with elevated colorectal and prostate cancer incidence (Kaaks et al., 2000, Eur J Cancer). This is not a reason to avoid MK-677 entirely, but it is a firm ceiling for dosing decisions.

Frequency of IGF-1 Testing

• Baseline: before starting
• Week 6: first on-cycle check
• Week 12: mid-cycle dose adjustment decision point
• Week 4 of washout: post-cycle baseline confirmation

Monitoring Labs: Full Panel and Rationale

MK-677's most clinically significant risk is insulin resistance. The Murphy RCT (N=187) documented a statistically significant increase in fasting glucose at 12 months in the MK-677 group compared with placebo (Murphy et al., 1998). The lab panel below addresses this and other known risk signals.

Metabolic Panel

| Lab | Baseline | Week 6 | Week 12 | Washout Week 4 | |---|---|---|---|---| | Fasting glucose | Yes | Yes | Yes | Yes | | HbA1c | Yes | No | Yes | Yes | | Fasting insulin | Yes | Yes | Yes | Yes | | HOMA-IR | Calculated | Calculated | Calculated | Calculated |

A HOMA-IR above 2.5 warrants dose reduction or cycle pause. Reference ranges for HOMA-IR are described in detail in Bonora et al. (Bonora et al., 2000, Diabetologia).

Hormonal Panel

| Lab | Baseline | Week 6 | Week 12 | |---|---|---|---| | IGF-1 | Yes | Yes | Yes | | GH (stimulated, optional) | Yes | No | Optional | | Total and free testosterone | Yes | No | Yes | | Prolactin | Yes | No | Yes | | Cortisol (AM) | Yes | No | Yes | | Thyroid (TSH, free T4) | Yes | No | Yes |

MK-677 increases cortisol transiently in some users. One crossover trial (N=8) documented a mean 21% increase in 24-hour urinary cortisol with 25 mg MK-677, though values remained within the laboratory reference range (Arvat et al., 2001, J Clin Endocrinol Metab).

Safety and Cardiovascular Panel

Blood pressure, complete metabolic panel, and a lipid panel should be drawn at baseline and every 12 weeks. Fluid retention is the primary cardiovascular concern and was reported in up to 20% of participants in the Nass 2-year trial at 25 mg (Nass et al., 2008). Sodium restriction and monitoring for edema are practical countermeasures.

Longevity Stack Combinations: Evidence and Cautions

Many biohackers combine MK-677 with other longevity compounds. The combinations below carry varying levels of evidence and specific interaction cautions.

MK-677 and Rapamycin

Rapamycin (sirolimus) inhibits mTORC1 and may blunt the anabolic signaling downstream of IGF-1. The two compounds have theoretically opposing effects on mTOR-driven protein synthesis. Some longevity practitioners use them on alternating days or alternating weeks to separate the anabolic stimulus (MK-677) from the autophagy-promoting mTORC1 inhibition (rapamycin). No human RCT has tested this combination directly. The rationale draws on animal data showing that intermittent rapamycin dosing preserves benefits while reducing immune suppression (Arriola Apelo et al., 2016, J Gerontol A Biol Sci Med Sci). Clinicians should monitor immune function labs if combining these agents.

MK-677 and Metformin

Metformin activates AMPK and may partially counteract the insulin-resistance signal from MK-677. This is a plausible rationale for co-administration, but the combination has not been tested in a controlled trial. Metformin's effect on mitochondrial complex I means that its interaction with GH-driven metabolic shifts is mechanistically complex (Fontaine, 2018, Front Endocrinol). If a patient's HOMA-IR rises on MK-677, adding or maintaining metformin is a reasonable clinical response, provided renal function supports it. The American Diabetes Association recommends monitoring eGFR before continuing metformin when values fall below 30 mL/min/1.73 m² (ADA Standards of Care 2024).

MK-677 and NAD+ Precursors (NMN, NR)

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are commonly stacked with MK-677 for purported synergistic effects on cellular energy metabolism and sirtuins. A 2023 RCT (N=30) of NMN supplementation showed a statistically significant increase in NAD+ levels and modest improvements in insulin sensitivity (Yoshino et al., 2021, Science). No trial has directly combined NMN or NR with MK-677. Because MK-677 may worsen insulin sensitivity and NMN may improve it, the combination is theoretically complementary, but clinical evidence is absent.

MK-677 and Peptides (BPC-157, CJC-1295, Ipamorelin)

Some practitioners layer MK-677 with injectable GHRH analogs like CJC-1295 or GHRP analogs like Ipamorelin to produce additive GH stimulation. This stacking strategy substantially raises IGF-1 above what MK-677 achieves alone. The risk of overshooting the IGF-1 ceiling (300 ng/mL) is meaningful. A study of CJC-1295 alone showed IGF-1 increases of 28 to 39% at doses of 30 to 60 mcg/kg (Teichman et al., 2006, J Clin Endocrinol Metab). Adding MK-677 on top could push IGF-1 well above safe targets. This combination requires weekly IGF-1 monitoring during initiation.

Sleep, Body Composition, and Cognitive Outcomes: What the Evidence Shows

Sleep Architecture

MK-677 reproducibly increases slow-wave sleep (SWS) duration. A crossover RCT (N=8 young adults, N=8 older adults) found that MK-677 25 mg increased SWS by 20 to 50% compared with placebo, with particularly pronounced effects in older participants (Copinschi et al., 1997). This is one of the most consistent findings in the MK-677 literature and directly relevant to longevity-focused users, given that SWS is the stage most associated with GH secretion, memory consolidation, and cellular repair.

Lean Mass and Bone Density

The Murphy RCT (N=187, 12 months) demonstrated a 1.4 kg increase in fat-free mass and a significant reduction in fat mass in older adults receiving MK-677 25 mg/day (Murphy et al., 1998). Bone turnover markers (osteocalcin, bone-specific alkaline phosphatase) also improved, consistent with findings from a separate 2-year trial showing increased bone mineral density in older men and women at 25 mg/day (Nass et al., 2008). These are the two strongest clinical endpoints for the longevity use case.

Cognitive Effects

Cognitive data on MK-677 are limited. GH and IGF-1 receptors are distributed throughout the hippocampus and prefrontal cortex, and low IGF-1 correlates with cognitive decline in observational data (Aleman et al., 1999, J Clin Endocrinol Metab). No RCT has yet shown MK-677 to improve standardized cognitive test scores in cognitively intact adults. The cognitive angle remains largely theoretical for now.

Side Effects, Contraindications, and Risk Management

MK-677's side effect profile is well-characterized from published trials. The most frequent adverse events at 25 mg are increased appetite (reported in 70 to 80% of users), mild lower-extremity edema (up to 20%), and elevated fasting glucose (clinically significant in roughly 10% of participants) (Nass et al., 2008).

Managing Appetite and Fluid Retention

The appetite increase from ghrelin receptor activation is dose-dependent. Switching from a morning to a bedtime dose often reduces daytime hunger without affecting IGF-1 response. Moderate sodium restriction (target <2,300 mg/day, per AHA guidelines) and adequate hydration typically resolve mild peripheral edema within 2 to 4 weeks (American Heart Association, Dietary Sodium).

Insulin Resistance Protocol

Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) should not start MK-677 without a concurrent metabolic management plan. If fasting glucose rises above 110 mg/dL on-cycle, dose reduction to 10 mg is the first step. If glucose exceeds 125 mg/dL, the cycle should be paused. The American Diabetes Association's 2024 Standards of Care define pre-diabetes thresholds and intervention criteria that apply directly here (ADA Standards of Care 2024).

Absolute Contraindications

• Active or history of GH-sensitive malignancy (prostate, breast, colorectal with elevated IGF-1 at diagnosis)
• Uncontrolled type 2 diabetes (HbA1c above 8%)
• Severe fluid-overload states (decompensated heart failure, nephrotic syndrome)
• Age <25 years with open epiphyses (theoretical risk of disproportionate growth)

The Endocrine Society's guideline on GH therapy explicitly cautions against use in patients with active malignancy and notes that IGF-1 elevation may stimulate residual tumor growth (Molitch et al., 2011).

Evidence Quality Summary

| Claim | Evidence Level | Key Source | |---|---|---| | MK-677 raises IGF-1 by 40 to 70% | Phase II RCT | Nass et al. 2008 | | Increases slow-wave sleep | Crossover RCT | Copinschi et al. 1997 | | Increases lean mass ~1.4 kg at 12 months | Phase II RCT | Murphy et al. 1998 | | Worsens insulin sensitivity | Phase II RCT | Murphy et al. 1998 | | Raises cortisol transiently | Crossover RCT (N=8) | Arvat et al. 2001 | | Rapamycin alternating-day protocol | Animal data only | Arriola Apelo et al. 2016 | | NMN/MK-677 combination benefit | No direct trial | Theoretical | | CJC-1295 additive IGF-1 stacking | Phase I/II RCT (CJC alone) | Teichman et al. 2006 |

The sleep and body composition endpoints carry the strongest evidence (Phase II RCTs with adequate power). The stacking protocols with rapamycin, NMN, or injectable peptides are supported only by mechanism-based reasoning and practitioner experience.

Timeline of Expected Outcomes

Patients and clinicians should set expectations against the clinical trial timelines, not influencer anecdotes.

| Timepoint | Expected Change | |---|---| | Day 7 to 14 | First measurable IGF-1 rise; increased appetite; possible early SWS improvement | | Week 4 to 6 | IGF-1 plateau at new steady state; appetite often partially adapts | | Week 8 to 12 | Lean mass gains begin to appear on DEXA (0.5 to 1.0 kg range) | | Month 6 to 12 | Bone turnover marker improvement; full lean mass effect (~1.4 kg over placebo) | | Post-cycle week 4 | IGF-1 returns toward baseline; insulin sensitivity recovers in most users |

Body weight may increase due to lean mass gain and fluid retention simultaneously. Tracking both scale weight and DEXA-derived lean mass every 12 weeks gives the most accurate picture of composition change.